A New Bio-marker Test for DCIS = Peace of Mind for Thousands of Women

peace-of-mindIf you are one of the 60,000 + women diagnosed with DCIS this year, you now have a way to gain more peace of mind about what to think and do about it.

A company called PreludeDx has scientifically validated a bio-marker test which evaluates a woman’s breast tissue sample and provides a “personalized” risk assessment based on her unique biology.

The test is called DCISionRT.

Had this test been available in 2010 when I was diagnosed with DCIS, I would have learned extremely valuable information that would have given me, my family AND my team of physicians great confidence in MY decisions.

Instead I found myself in a very lonely place. I was continually scared and pressured by physicians as well as women in online DCIS forums to succumb to aggressive cancer treatments — procedures and drugs that felt more toxic, scary and harmful than the actual DCIS diagnosis.

Fast forward 8.5 years.

The PreludeDx team discovered my story and arranged to test my original DCIS biopsy tissue from 2010.

Troy-Bremer
According to Troy Bremer, co-founder and Chief Scientific Officer at PreludeDx, “You have very clean biology for DCIS.”

He personally went over the results of my DCISionRT test with me which you can see below.

My Score was less than 1 out of 10 (0.8 / 10), with 9% risk of total 10-year recurrence and no expected benefit from radiation therapy.

Prelued Risk Results_DonnaIs this the picture of a woman in need of a mastectomy or weeks of daily radiation?

Is this someone who deserved to be told by a breast cancer physician, “Don’t be stupid Donna… at least do 3 weeks of radiation.

Unfortunately, DCISionRT was not available in 2010.

While I am thankful I had my strong intuition and a number of articles and studies on suspected overdiagnosis and overtreatment of DCIS, I now have the scientific proof that I  made the right choices and said NO to weeks of radiation or mastectomy.

Hopefully thousands of women today can be spared the frightening feeling that comes with uncertainty and can instead have more personalized information to support their decisions for active surveillance if they are low-risk rather than be continually pressured towards a one-size-fits-all highly aggressive treatment protocol.

In the past, studies have shown 97% of women end up doing aggressive treatments for DCIS. confusedLack of knowledge about the biological nature of DCIS coupled with fear and anxiety have been strong motivators.

Not only does DCISionRT give a woman and her family tremendous peace of mind, it can provide physicians the scientific evidence to feel more confident in supporting both someone like me — with a low-risk DCIS — to someone who is at a more elevated risk.

I believe DCISionRT will help shift the paradigm away from needless emotional trauma, (worry, overwhelm, confusion, uncertainty, intimidation and fear),  as well as help stop the problem known as “over-treatment” of DCIS.

I hope all health-care providers and organizations concerned with “early detection” of breast cancer embrace this important test.

When it comes to DCIS, there is no price tag for peace of mind.

PreludeDx_Tyler_Donna_Jenn

Jennifer Cohrs, PreludeDx Marketing Manager, Donna Pinto, DCIS411.com, Tyler H. Kibbee
Vice President, Strategic Marketing

If your doctor is unaware or unsupportive of DCISionRT, please contact Jennifer Cohrs for assistance:

I recently enjoyed a lab tour and meeting with the PreludeDx team at their office in Laguna, California.

Thank you Prelude Dx for advancing the science of DCIS and for treating me like a VIP!

To learn more about DCISionRT, click here.

Posted in Health, Options, Personal Stories, Resources, Sanity, Support | Tagged , , , , , , , , , , , , , | 1 Comment

DCIS — Beyond “One-Size Fits-All”

Today, women newly diagnosed with DCIS have more support, options, and resources than ever before.

Below are eight ways to help you create an “individualized” and empowered plan-of-action…

#1.  CONFIRM YOUR PATHOLOGY

#2.  ASK YOUR DOCTOR TO ORDER A BIOLOGICAL RISK ASSESSMENT TEST

#3.  JOIN A PEER SUPPORT GROUP

#4.  REVIEW PATIENT WEBSITES

 

#5. CONSIDER A CLINICAL TRIAL COMPARING ACTIVE SURVEILLANCE TO SURGERY

#6.  INCORPORATE LIFESTYLE STRATEGIES

 

#7.  UNDERSTAND LIMITATIONS OF MAMMOGRAMS

#8. STAY “IN THE KNOW” OF EMERGING RESEARCH

  • PRECISION is an international research project aimed at distinguishing indolent from aggressive DCIS in order to reduce overtreatment and life-long side effects.
  • Set up a Google Alert for “DCIS”

 

 

Posted in Health, Options, Resources, Sanity, Support | Tagged , , , , , , , , , , , , , , , | Leave a comment

Evaluating DCIS treatments — do you know your “survival” statistics?

facts not fear“There is strong evidence that treatment of DCIS in most women has no clear effect on mortality reduction.” – Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS)

“Risk of development of metastases and/or death in a patient diagnosed with pure DCIS is very low (<1%).Ductal Carcinoma-In-Situ of the Breast with Subsequent Distant Metastasis and Death

SURGERY

RADIATION

TAMOXIFEN

  • While tamoxifen after local excision for DCIS (with or without adjuvant radiotherapy) reduced the risk of recurrent DCIS (in the ipsi- and contralateral breast), it did not reduce the risk of overall mortality. – Postoperative tamoxifen for ductal carcinoma in situ.
  • Warrick and Allred in their editorial piece conclude that tamoxifen is probably overused, and advocate more selective use. They particularly note that the major benefit would be seen in patients who are younger (premenopausal) with extensive high grade disease and/or narrow margins, and clearly only those that are ER positive.In conclusion, the clinical benefit of tamoxifen intervention based on the randomized trials is meager at best. There appears to be no benefit, at least in the UK/ANZ trial for tamoxifen amongst irradiated patients, and the benefits when claimed are very small. – Tamoxifen as an Adjuvant Agent for Ductal Carcinoma In Situ (DCIS)

 

Posted in Health, Options, Resources, Support | Tagged , , , , , , , , , | 2 Comments

Namaste — My 4-11 Blessing to All

Today is 4-11 — a perfect day for a quick check-in… and “namaste” blessing to all!

On April 1, I celebrated my birthday with a visit to the Self Realization Fellowship Mediation Gardens in Encinitas.

I said a prayer of gratitude and wished for everyone to have the blessings of  love, truth, light, (health) and peace — the meaning of my word for the year — “namaste.”

One friend who is in my heart and soul is Sandie Walters.

I was so shocked and sad to learn that Sandie died suddenly from pneumonia in January. Sandie’s spirit will live on forever through DCIS Redefined, a website we created together in 2013.

I am so thankful for the meaningful work I am involved with along with my health, my family and all my dear friends near and far!

Wishing everyone peace, love, light, health and truth.

~ NAMASTE ~

Donna Pinto, 4-11-18

 

 

Posted in Health | 3 Comments

Keeping Patient Perspectives at the Forefront of DCIS Research

COMET PLTPatient Advocates from across the US and around the world came together to share insights about DCIS at the 2017 San Antonio Breast Cancer Symposium.

The COMET Study Patient Leadership Team presented “Changing the DCIS Conversation: Development of an Alternative Discourse by Patient Advocate Stakeholders in the COMET Study.”

PLT POSTER

Ellen Jelle Deb DonnaAdvocates from the US, UK and the Netherlands highlighted their role as “partners” on PRECISION — “PREvent ductal Carcinoma In Situ Invasive Overtreatment Now.”

This international initiative was awarded Cancer Research UK’s Grand Challenge. Led by Dr. Jelle Wesseling of the Netherlands Cancer Institute, PRECISION aims to distinguish between lethal cancers that need treating, and non-lethal cancers that don’t.

 

Help keep patient perspectives at the forefront of DCIS research!  Join the conversation by commenting below or on social media!

 

 

 

 

Posted in Health | Tagged , , , , , | 4 Comments

Active Surveillance P L U S — Donna’s Vision

“Active surveillance” of a potential cancerous condition through periodic medical imaging in itself can be extremely stressful — and the anxiety, worry and fear of cancer developing or progressing may not go away as time goes on.   balance

Active Surveillance P L U S is my vision. It is a holistic approach to cancer prevention, risk reduction and optimal wellness — and this strategy should not be considered “alternative.”

P L U S stands for Proactive – Lifestyle – Understanding – Support

P R O A C T I V E

Action and result-oriented strategies which can help reduce cancer risk and keep us feeling empowered, supported, centered, optimistic, and healthy (body, mind & spirit). See “Proactive Breast Health Club.”  

L I F E S T Y L E

Holistic wellness is not a diet or exercise plan. It is a combination of influential factors — a way of living, thinking and being — supported by scientific evidence to be protective against cancer. See Anticancer Living: The Mix of Six 

U N D E R S T A N D I N G

Knowledge is power. Investigate until you have a deep understanding of both your individual medical condition and how the body heals through a combination of holistic mind-body-spirit strategies. Review Donna’s resources here; read articles and watch videos compiled by Donna and Sandie Walters here.

S U P P O R T

Support is a critical factor in optimal health outcomes. See ways to stay connected below.

Donna’s Vision…

Active Surveillance P L U S is…

Donna_give_wellness

  • recognized as standard “preventative care” which significantly reduces cancer-care costs, stress and unnecessary harm.
  • embraced and encouraged by all (including medical professionals).
  • not considered “alternative.”
  • covered by insurance.
  • inclusive of safe imaging modalities with women’s personal values and preferences taken into consideration.

Ways to Stay Connected & Supported:

Posted in Health, Options, Personal Stories, Sanity, Support | Tagged , , , , , , , , , , , , , | 2 Comments

Aggressive Treatments for DCIS — or NOT? New Research Sheds Light

photo-1440968872456-dec3196b9bee - Copy (2)Where are the studies of women (like me) who have taken a less aggressive path for “low-risk” DCIS? 

Until now — they didn’t exist.

Thanks to $13.4 million in funding from the Patient-Centered Outcomes Research Institute (PCORI), a long over-due clinical trial for DCIS has officially launched.

comet-logo

It’s called The COMET Study.

The goal is to learn if women with low-risk DCIS can avoid aggressive treatments and their physical and/or emotional side effects.

COMET stands for Comparison of Operative to Monitoring and Endocrine Therapy. It is a randomized prospective study that will enroll 1200 women at 100 cancer centers throughout the US.

My Role as a Patient Advocate

comet_3In 2016, I was invited to be one of four patient advocates on The COMET Study team.

We have enjoyed the opportunity to keep patient perspectives at the forefront of the study as well as this new website: www.dcisoptions.org

Since my DCIS diagnosis in 2010, I have been following and sharing the forward-thinking wisdom of a handful of breast cancer experts who were speaking out for the need for studies like COMET. It is such a blessing to now be working with some of these compassionate doctors who are leading the COMET Study…

In this video Dr. Shelley Hwang and I share patient and physician perspectives on DCIS.

 

donna-pinto_2016

Donna Pinto, DCIS 411

I hope every woman diagnosed with low-risk DCIS today knows they have a great opportunity that did not exist for me (and thousands others) in the past.

I feel an incredible sense of gratitude to all the forces and people that have made the COMET Study possible — to the physicians and cancer centers who are making it available — and to the women who will participate. Thank you!

 

A 2nd Project Takes DCIS Research Global 

funded-teams-hero-1_0I’m honored, thrilled, humbled and grateful to be a part of an international team of scientists and patient advocates from the UK, the Netherlands, and the US on a 2nd paradigm-shifting research project.

 

Preventing Unnecessary logoBreast Cancer Treatment  was recently awarded 15 million pounds by Cancer Research UK’s Grand Challenge.

The goal is to identify bio-markers that can distinguish DCIS patients with a low risk of developing cancer from patients with a high risk.

jelle-wesseling_150x150In this video, Jelle Wesseling, pathologist from the Netherlands Cancer Institute, discusses the need to be able to distinguish harmless DCIS from the potentially hazardous DCIS.

This research may help spare thousands of women unnecessary treatment.

More similar studies in Europe and the UK

  1. Management of Low-risk DCIS (LORD)
  2. The LORIS Trial: Addressing Overtreatment of Ductal Carcinoma In Situ

francis-adeleSadly, just as I was getting acquainted with the work of Adele Francis (LORIS trial Principal Investigator), I learned of her sudden passing.

Although I did not know Adele personally, when I watched this video, I felt we we were kindred spirits.

So many lives have been blessed by Adele’s work and passion. May her spirit and wisdom continue to shine down upon all of us.

~ Donna Pinto, @DCIS411

“Travel Light. Live Light. Spread the Light. Be the Light.”

 

 

Posted in Health, Options, Personal Stories, Resources, Sanity, Support | Tagged , , , , , , , | 10 Comments